A5057725652- Cell death mechanisms and regulation
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Esophageal and GI Pathology
- interferon and immune responses
- Pancreatic and Hepatic Oncology Research
- Glioma Diagnosis and Treatment
- NF-κB Signaling Pathways
- Liver Disease Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Cancer Research and Treatments
- Head and Neck Surgical Oncology
- Hepatitis C virus research
- Clinical Nutrition and Gastroenterology
- Organ Transplantation Techniques and Outcomes
- Meningioma and schwannoma management
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Ferroptosis and cancer prognosis
- Cardiac electrophysiology and arrhythmias
- Gastric Cancer Management and Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Cancer, Lipids, and Metabolism
Heidelberg University
2016-2025
University Hospital Heidelberg
2015-2025
RELX Group (Netherlands)
2022
University Gastroenterology
2015
German Cancer Research Center
2005-2014
Tel Aviv Sourasky Medical Center
2014
Medizinische Hochschule Hannover
2014
Chirurgische Universitätsklinik Heidelberg
2005-2012
Leipzig University
2002-2009
Goethe University Frankfurt
2009
Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1) blockade in cancer patients, but mechanisms underlying their immunosuppressive effects remain unknown. By inducing down-regulation mucosal addressin adhesion molecule (MAdCAM-1) ileum, post-ABX gut recolonization by Enterocloster species drove emigration enterotropic α4β7+CD4+ regulatory T 17 cells into tumor. These deleterious ABX were mimicked oral gavage species, genetic deficiency, or antibody-mediated...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) exhibits potent antitumor activity on systemic administration in nonhuman primates without deleterious side effects for normal tissue. However, there is a controversy about the potential toxicity of TRAIL human hepatocytes. The use different recombinant forms only partially explains contradicting reports sensitivity primary hepatocytes (PHH).To clarify this issue, we comprehensively tested four their capacity PHH obtained...
Death rates from hepatocellular carcinoma (HCC) are steadily increasing, yet therapeutic options for advanced HCC limited. We identify a subset of mouse and human HCCs harboring VEGFA genomic amplification, displaying distinct biologic characteristics. Unlike common tumor amplifications, this one seems to work via heterotypic paracrine interactions; stromal VEGF receptors (VEGFR), responding VEGF-A, produce hepatocyte growth factor (HGF) that reciprocally affects cells. VEGF-A inhibition...
Abstract TRAIL exhibits potent anti-tumor activity on systemic administration in mice. Because of its proven vivo efficacy, may serve as a novel anti-neoplastic drug. However, approximately half the tumor cell lines tested so far are resistant, and potential toxic side effects certain recombinant forms human hepatocytes have been described. Pretreatment with proteasome inhibitor MG132 PS-341 rendered TRAIL-resistant hepatocellular carcinoma (HCC) but not primary sensitive for TRAIL-induced...
Hepatitis C virus (HCV) infection is sensitive to interferon (IFN)-based therapy, whereas hepatitis B (HBV) not. It unclear whether HBV escapes detection by the IFN-mediated immune response or actively suppresses it. Moreover, little known on how and HCV influence each other in coinfected cells. We investigated interactions between using HepaRG cells primary human hepatocytes (PHHs). analyzed effects of replication, vice versa, at single-cell level.PHHs were isolated from liver resection...
Abstract Purpose: Malignant gliomas are the most aggressive human brain tumors without any curative treatment. The antitumor effect of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) in has thus far only been thoroughly established cell lines. In present study, we investigated therapeutic potential TRAIL primary glioma cells. Experimental Design: We isolated cells from 13 astrocytoma and oligoastrocytoma patients all four WHO grades malignancy compared levels TRAIL-induced...
Abstract Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) represents a novel promising anticancer biotherapeutic. However, TRAIL-resistant tumor cells require combinatorial regimens to sensitize but not normal for TRAIL-induced apoptosis. Here, we investigated the mechanism of synergistic antitumor effect bortezomib in combination with TRAIL hepatoma, colon, and pancreatic cancer comparison toxicity primary human hepatocytes (PHH). cotreatment at high clinically relevant...
Abstract Purpose: Sorafenib is the only currently approved systemic therapy for advanced hepatocellular carcinoma (HCC). We aimed to evaluate safety and efficacy of sorafenib in patients with HCC under real-life conditions regarding patient, tumor characteristics, any adverse events at study entry follow-up visits every 2 4 months. Experimental Design: The current INSIGHT a noninterventional, prospective, multicenter, observational performed 124 sites across Austria Germany between 2008...
Hepatitis C virus (HCV) infections most often result in chronic outcomes, although the constantly produces replication intermediates, particular double-stranded RNA (dsRNA), representing potent inducers of innate immunity. We aimed to characterize fate HCV dsRNA hepatocyte cultures identify mechanisms contributing viral persistence presence an active immune response.We analyzed hepatocyte-based culture models for induction immunity, secretion positive- or negative-strand RNA, and using...
Scheduled endoscopic dilatation of dominant strictures (DS) in primary sclerosing cholangitis (PSC) might improve outcome relative to treatment on demand, but evidence is limited. Since randomisation difficult clinical practice, we present a large retrospective study comparing scheduled versus on-demand retrograde cholangiopancreatography (ERCP) based patient preferences.Between 1987 and 2017, all new patients with PSC had been offered ERCP DS if diagnosed; the latter was repeated at defined...
Article26 July 2021Open Access Source DataTransparent process Single-cell transcriptomics reveals immune response of intestinal cell types to viral infection Sergio Triana orcid.org/0000-0003-0370-7821 Structural and Computational Biology Unit, European Molecular Laboratory, Heidelberg, Germany Faculty Biosciences, Collaboration for Joint PhD degree between EMBL Heidelberg University, These authors contributed equally this work Search more papers by author Megan L Stanifer...
<b><i>Objective:</i></b> This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment. <b><i>Methods:</i></b> Between December 2007 and January 2010, 46 HCC were treated until significant tumor progression or intolerable toxicity. We prospectively collected baseline data as well on the incidence severity of toxic side effects be correlated...
Zusammenfassung Die endoskopische retrograde Cholangiopankreatikografie (ERCP) wird im Zusammenhang mit der Cholezystektomie (CHE) u. a. bei Verdacht auf Gallengangssteine durchgeführt. ERCP ist aufgrund ihrer Invasivität eine Untersuchung relevanter Morbidität und Mortalität kann einen Einfluss den perioperativen Verlauf CHE haben. Im Rahmen dieser retrospektiven monozentrischen Studie wurden konsekutiv alle Patienten von 01.07.2018 bis 31.12.2022, die sich in Baden-Baden einer unterzogen,...